Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Scribe Therapeutics Inc. Common Stock

SCTX

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

Last trade $15.88
Day change +$0.51 (+3.32%)
Day range $14.60 – $16.25
Volume 204,428
Market cap $291M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for SCTX.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for SCTX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026
Revenue$1.64M
Cost of revenue$0
Gross profit$1.64M
Selling, general and administrative$4.24M
Research and development$8.26M
Total operating expenses$12.5M
Operating income-$10.86M
Interest expense$0
Income before taxes-$9.63M
Income taxes$231K
Net income-$9.86M
Net income attributable to common shareholders-$9.86M
EBITDA-$10.24M
Basic earnings per share-$0.68
Diluted earnings per share-$0.68

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
The Motley Fool

Cathie Wood Bought Just 3 Stocks On Monday; Here They Are

Cathie Wood's Ark Invest made selective purchases on Monday, adding to positions in Nvidia, SoFi Technologies, and Scribe Therapeutics despite a generally bullish market day. Nvidia faced headwinds from a spy scandal investigation involving CEO Jensen Huang but remains attractively valued. SoFi showed strong fundamentals with 35% member growth and 44% revenue increase, though it's down 41% over the past year. Scribe Therapeutics, a gene-editing biotech, has sufficient cash runway through early 2029.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.